Taglich Brothers Initiates Coverage of Ocean Biomedical, Inc.
May 31, 2023 09:30 ET
|
Taglich Brothers Inc
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Taglich Brothers, Inc. announces that it has initiated coverage of Ocean Biomedical, Inc. (NASDAQ: OCEA). Ocean Biomedical, Inc. headquartered in...
FFF Enterprises Inc. and RightNow Inventory™ Become Vital Members of the Artesunate for Injection Distribution Network
March 08, 2023 13:34 ET
|
FFF Enterprises.com
Temecula, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- FFF Enterprises Inc., the nation’s most trusted specialty drug distributor, today announced that it has partnered with Amivas (US), LLC to stock...
Ocean Biomedical to Ring The Nasdaq Stock Market Opening Bell
February 16, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Ocean Biomedical commenced trading on Nasdaq under ticker symbol "OCEA" on February 15 Providence, RI and New York, NY, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (“the Company”),...
Malaria Pipeline Clinical Trials Featuring 35+ companies| DelveInsight
January 04, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Malaria Pipeline Clinical Trials Featuring 35+ companies| DelveInsight Malaria is one of the most widespread life-threatening diseases, commonly...
BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
December 23, 2022 03:00 ET
|
BioNTech SE
BioNTech aims to develop the first mRNA-based vaccine for Malaria prevention based on a novel multi-antigen vaccine approachFirst evaluated candidate BNT165b1 expresses certain parts of the...
BioNTech beginnt klinische Phase-1-Studie mit Malaria-Impfstoffprogramm BNT165
December 23, 2022 03:00 ET
|
BioNTech SE
BioNTechs Ziel ist es, den ersten mRNA-basierten Impfstoff zur Prävention von Malaria zu entwickeln, der auf einem neuartigen Multi-Antigen-Impfstoffansatz basiert.Der erste in der Klinik untersuchte...
BioNTech Starts Construction of First mRNA Vaccine Manufacturing Facility in Africa
June 23, 2022 06:00 ET
|
BioNTech SE
Breaking of Ground for BioNTech’s initial African modular mRNA manufacturing facility in Kigali, Rwanda; delivery of first container modules planned for end of 2022On invitation by H.E. President Paul...
BioNTech beginnt Bau der ersten Produktionsstätte für mRNA-basierte Impfstoffe in Afrika
June 23, 2022 06:00 ET
|
BioNTech SE
Spatenstich in Kigali, Ruanda, für BioNTechs erste modulare mRNA-Produktionsstätte in Afrika; Lieferung der ersten Containermodule für Ende 2022 geplantAuf Einladung von Paul Kagame, Präsident der...
Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
June 22, 2022 20:01 ET
|
Novartis Pharma AG
Novartis endorses the Kigali Declaration on neglected tropical diseases, pledging USD 250 million to advance R&D of new treatments against NTDs and malaria over five yearsCommitment includes USD...
New Study Identifies Potential Immunotherapy Target for Malaria
May 09, 2022 10:00 ET
|
Experimental Biology and Medicine
WASHINGTON, May 09, 2022 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine (Volume 247, Issue 8, April, 2022) identifies a new target for malaria treatment. The...